Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076011 · ClinicalTrials.gov registry record · Phase 2
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
A Phase 2 study of Kidney Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 9
- Study locations
NCT00076011 is a Phase 2 study of Kidney Neoplasms that has completed, run by Pfizer. The registered enrollment target is 52 participants, below the 382-participant average among 9 other Kidney Neoplasms trials with a reported enrollment target (86% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT00076011, a Phase 2 study of Kidney Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 9
- Study locations
Study Summary
The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.
Conditions Studied
Interventions
- DRUG Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor
Study Locations (9)
Massachusetts
- Pfizer Investigational Site - Boston
- Pfizer Investigational Site - Boston
California
- Pfizer Investigational Site - San Francisco
New York
- Pfizer Investigational Site - New York
Ohio
- Pfizer Investigational Site - Cleveland
Pennsylvania
- Pfizer Investigational Site - Philadelphia
Wisconsin
- Pfizer Investigational Site - Madison
Paris
- Pfizer Investigational Site - Paris
Other
- Pfizer Investigational Site - Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076011
The ClinicalTrials.gov registry entry for NCT00076011 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 382-participant average among 9 other Kidney Neoplasms trials with a reported enrollment target (86% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor is the first listed.
NCT00076011 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Massachusetts, California, New York.
Frequently Asked Questions
What is clinical trial NCT00076011 about?
NCT00076011 is a clinical study titled "Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma". The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.
What is the current status of trial NCT00076011?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2003-10. Estimated completion is 2007-02.
What conditions does trial NCT00076011 study?
This clinical trial studies the following conditions: Kidney Neoplasms.
What interventions are being tested in trial NCT00076011?
The interventions under investigation include: Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor (DRUG).
Who is sponsoring clinical trial NCT00076011?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00076011 being conducted?
This trial has 9 study locations across California, Massachusetts, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
RECRUITING · Phase 2
-
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
COMPLETED · Phase 2
-
Cabozantinib for Advanced Urothelial Cancer
COMPLETED · Phase 2
-
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
RECRUITING
-
Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach
RECRUITING · NA
-
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.